Opus Genetics Inc
IRD2.025USD
+0.025+1.25%
Market hours （ET）Quotes delayed by 15 min
130.70MMarket Cap
LossP/E TTM
More Details of Opus Genetics Inc Company
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Opus Genetics Inc Info
Ticker SymbolIRD
Company nameOpus Genetics Inc
IPO dateNov 30, 2004
CEOMagrath (George)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 30
Address8 Davis Drive
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27713
Phone12486819815
Websitehttps://opusgtx.com/
Ticker SymbolIRD
IPO dateNov 30, 2004
CEOMagrath (George)
Company Executives of Opus Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
630.61K
-8.78%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
254.82K
+51.80%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
200.00K
--
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
President, Director
10.00K
-97.08%
Dr. Ash Jayagopal, Ph.D.
Dr. Ash Jayagopal, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
--
--
Dr. James S. Manuso
Dr. James S. Manuso
Independent Director
Independent Director
--
--
Dr. Jean Bennett, M.D., Ph.D.
Dr. Jean Bennett, M.D., Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
630.61K
-8.78%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
254.82K
+51.80%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
200.00K
--
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foundation Fighting Blindness Inc
7.96%
Perceptive Advisors LLC
6.27%
Bios Equity Partners, LP.
5.34%
Nantahala Capital Management, LLC
4.85%
Gallagher (Cam S)
2.63%
Other
72.95%
Shareholders
Shareholders
Proportion
Foundation Fighting Blindness Inc
7.96%
Perceptive Advisors LLC
6.27%
Bios Equity Partners, LP.
5.34%
Nantahala Capital Management, LLC
4.85%
Gallagher (Cam S)
2.63%
Other
72.95%
Shareholder Types
Shareholders
Proportion
Hedge Fund
9.26%
Corporation
7.96%
Individual Investor
6.33%
Private Equity
6.27%
Venture Capital
5.42%
Investment Advisor
3.48%
Investment Advisor/Hedge Fund
3.01%
Research Firm
0.13%
Bank and Trust
0.02%
Other
58.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
108
17.84M
28.30%
-450.90K
2025Q2
129
27.24M
45.65%
+17.32M
2025Q1
138
20.65M
39.75%
+13.58M
2024Q4
131
8.86M
28.50%
+3.96M
2024Q3
122
4.55M
16.47%
-580.64K
2024Q2
124
4.74M
17.35%
-706.54K
2024Q1
127
5.24M
21.33%
-1.10M
2023Q4
122
5.21M
22.35%
-525.41K
2023Q3
117
4.91M
22.05%
-1.09M
2023Q2
119
4.95M
23.60%
-1.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foundation Fighting Blindness Inc
9.49M
15.06%
+6.93M
+270.10%
Apr 30, 2025
Perceptive Advisors LLC
4.33M
6.86%
--
--
Jun 30, 2025
Bios Equity Partners, LP.
3.68M
5.84%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
3.35M
5.31%
+188.03K
+5.95%
Jun 30, 2025
Gallagher (Cam S)
1.81M
2.87%
+869.57K
+92.42%
Aug 25, 2025
The Vanguard Group, Inc.
992.20K
1.57%
--
--
Jun 30, 2025
Mink Brook Asset Management LLC
1.20M
1.9%
+387.54K
+47.84%
Jun 30, 2025
Opaleye Management Inc.
1.22M
1.94%
+45.00K
+3.83%
Jun 30, 2025
Bleichroeder LP
736.84K
1.17%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Value ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
Proportion0%
Avantis US Small Cap Value ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Date
Type
Ratio
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
Nov 05, 2020
Merger
4→1
FAQs
Who are the top five shareholders of Opus Genetics Inc?
The top five shareholders of Opus Genetics Inc are:
Foundation Fighting Blindness Inc holds 9.49M shares, accounting for 15.06% of the total shares.
Perceptive Advisors LLC holds 4.33M shares, accounting for 6.86% of the total shares.
Bios Equity Partners, LP. holds 3.68M shares, accounting for 5.84% of the total shares.
Nantahala Capital Management, LLC holds 3.35M shares, accounting for 5.31% of the total shares.
Gallagher (Cam S) holds 1.81M shares, accounting for 2.87% of the total shares.
Foundation Fighting Blindness Inc holds 9.49M shares, accounting for 15.06% of the total shares.
Perceptive Advisors LLC holds 4.33M shares, accounting for 6.86% of the total shares.
Bios Equity Partners, LP. holds 3.68M shares, accounting for 5.84% of the total shares.
Nantahala Capital Management, LLC holds 3.35M shares, accounting for 5.31% of the total shares.
Gallagher (Cam S) holds 1.81M shares, accounting for 2.87% of the total shares.
What are the top three shareholder types of Opus Genetics Inc?
The top three shareholder types of Opus Genetics Inc are:
Foundation Fighting Blindness Inc
Perceptive Advisors LLC
Bios Equity Partners, LP.
Foundation Fighting Blindness Inc
Perceptive Advisors LLC
Bios Equity Partners, LP.
How many institutions hold shares of Opus Genetics Inc (IRD)?
As of 2025Q3, 108 institutions hold shares of Opus Genetics Inc, with a combined market value of approximately 17.84M, accounting for 28.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.36%.
What is the biggest source of revenue for Opus Genetics Inc?
In --, the -- business generated the highest revenue for Opus Genetics Inc, amounting to -- and accounting for --% of total revenue.
